WallStreetZenWallStreetZen

NYSE: ABT
Abbott Laboratories Stock

Overview
ForecastEarningsDividendOwnership
$109.95-1.12 (-1.01%)
Updated Jan 27, 2023
ABT Price
$109.95
Fair Value Price
N/A
Market Cap
$191.71B
52 Week Low
$93.25
52 Week High
$130.94
P/E
24.6x
P/B
5.34x
P/S
3.77x
PEG
3.09x
Dividend Yield
1.75%
Revenue
$45.03B
Earnings
$7.89B
Gross Margin
57.1%
Operating Margin
21.87%
Profit Margin
17.5%
Debt to Equity
1.03
Operating Cash Flow
$10B
Beta
0.86
Next Earnings
N/A
Ex-Dividend
Jan 12, 2023
Next Dividend
Feb 15, 2023

ABT Overview

Abbott Laboratories is a medical device and health care company. Its products include various medical devices, diagnostic tools and technologies, branded generic medicines, and nutritional products. Among its well-known brands are Pedialyte, Similac, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip. The company was founded in 1888 and is headquartered in Abbott Park, IL.

Zen Score

–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ABT scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ABT ($109.95) is trading above its intrinsic value of $39.37, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ABT is poor value based on its earnings relative to its share price (24.6x), compared to the US market average (23.59x)
P/E vs Market Valuation
ABT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more ABT due diligence checks available for Premium users.

Be the first to know about important ABT news, forecast changes, insider trades & much more!

ABT News

Valuation

ABT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
24.6x
Industry
57.58x
Market
23.59x
ABT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ABT is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

ABT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
5.34x
Industry
3.56x
ABT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ABT price to earnings growth (PEG)

For valuing profitable companies with growth potential
ABT is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

ABT's financial health

Profit margin

Revenue
$10.4B
Net Income
$1.4B
Profit Margin
13.8%
ABT's Earnings (EBIT) of $9.85B... subscribe to Premium to read more.
Interest Coverage Financials
ABT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$72.8B
Liabilities
$36.9B
Debt to equity
1.03
ABT's short-term assets ($24.85B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABT's short-term assets ($24.85B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ABT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$2.8B
Investing
-$484.0M
Financing
-$1.5B
ABT's operating cash flow ($10.32B)... subscribe to Premium to read more.
Debt Coverage Financials

ABT vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
ABT$191.71B-1.01%24.60x5.34x
MDT$109.85B+0.90%25.57x2.12x
SYK$96.19B+0.70%39.10x5.84x
BSX$65.76B-0.95%111.98x3.73x
EW$48.31B-0.09%33.39x7.77x
View Top Medical Device Stocks

Abbott Laboratories Stock FAQ

What is Abbott Laboratories's quote symbol?

NYSE: ABT) Abbott Laboratories trades on the NYSE under the ticker symbol ABT. Abbott Laboratories stock quotes can also be displayed as NYSE: ABT.

If you're new to stock investing, here's how to buy Abbott Laboratories stock.

What is the 52 week high and low for Abbott Laboratories (NYSE: ABT)?

(NYSE: ABT) Abbott Laboratories's 52-week high was $130.94, and its 52-week low was $93.25. It is currently -16.03% from its 52-week high and 17.91% from its 52-week low.

How much is Abbott Laboratories stock worth today?

(NYSE: ABT) Abbott Laboratories currently has 1,743,573,777 outstanding shares. With Abbott Laboratories stock trading at $109.95 per share, the total value of Abbott Laboratories stock (market capitalization) is $191.71B.

Abbott Laboratories stock was originally listed at a price of $32.75 in Dec 31, 1997. If you had invested in Abbott Laboratories stock at $32.75, your return over the last 25 years would have been 235.73%, for an annualized return of 4.96% (not including any dividends or dividend reinvestments).

How much is Abbott Laboratories's stock price per share?

(NYSE: ABT) Abbott Laboratories stock price per share is $109.95 today (as of Jan 27, 2023).

What is Abbott Laboratories's Market Cap?

(NYSE: ABT) Abbott Laboratories's market cap is $191.71B, as of Jan 28, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Abbott Laboratories's market cap is calculated by multiplying ABT's current stock price of $109.95 by ABT's total outstanding shares of 1,743,573,777.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.